Studies have indicated that miR-148a inhibits excessive autophagy activation and inflammatory responses by modulating the IL-6/STAT3 signaling axis in both in vitro and in vivo models of cerulein-induced AP, suggesting that miR-148a is a potential candidate for AP gene therapy (104, 105). The gene discussed is IL6; the disease is alkaline phosphatase measurement.